Equity Details
Price & Market Data
Price: $0.63
Daily Change: +$0.0187 / 2.97%
Daily Range: $0.61 - $0.645
Market Cap: $4,789,741
Daily Volume: 26,772
Performance Metrics
1 Week: -1.42%
1 Month: -17.29%
3 Months: -29.92%
6 Months: -48.30%
1 Year: -48.73%
YTD: -37.87%
About Mustang Bio, Inc. (MBIO)
Get the full story on Mustang Bio, Inc. (MBIO). Price: 0.63, daily change: +$0.0187 / 2.97%. Market cap: 4,789,741. Performance from YTD to 1-year is available.
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
